96 related articles for article (PubMed ID: 38570507)
1. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
2. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis.
Yamada K; Takeuchi M; Fukumoto T; Suzuki M; Kato A; Mizuki Y; Yamada N; Kaneko T; Mizuki N; Horita N
Sci Rep; 2024 Apr; 14(1):7887. PubMed ID: 38570507
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
Pham JP; On L; Ardolino L; Hurwitz J; Salaun H; Sim HW; Joshua AM
Melanoma Res; 2023 Aug; 33(4):316-325. PubMed ID: 37199712
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
10. Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H; Somekawa K; Horita N; Ueda S; Kaneko M; Kaneko A; Fukuda N; Izawa A; Kamimaki C; Tanaka K; Murohashi K; Fuji H; Tagami Y; Aoki A; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2023; 15():17588359231198453. PubMed ID: 37720498
[TBL] [Abstract][Full Text] [Related]
11. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy.
Pradeep J; Win TT; Aye SN; Sreeramareddy CT
J Cancer; 2022; 13(10):3091-3102. PubMed ID: 36046644
[No Abstract] [Full Text] [Related]
13. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis.
Zhu Y; Cheng H; Zhong M; Hu Y; Li Q; Gao X; Liu S
J Cancer Res Ther; 2021 Dec; 17(7):1679-1688. PubMed ID: 35381739
[TBL] [Abstract][Full Text] [Related]
14. Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K; Horita N; Kaneko A; Tagami Y; Fukuda N; Matsumoto H; Namkoong H; Fujiwara Y; Minegishi K; Fukumoto T; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2022; 14():17588359211058393. PubMed ID: 35173819
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity.
Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158786
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
